| 0.2693 -0.124 (-31.46%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.4 |
1-year : | 0.47 |
| Resists | First : | 0.34 |
Second : | 0.4 |
| Pivot price | 0.28 |
|||
| Supports | First : | 0.23 |
Second : | 0.19 |
| MAs | MA(5) : | 0.32 |
MA(20) : | 0.29 |
| MA(100) : | 0.47 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 62.1 |
D(3) : | 69.7 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 2.33 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FBLG ] has closed above bottom band by 39.1%. Bollinger Bands are 15.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.3 - 0.31 | 0.31 - 0.31 |
| Low: | 0.25 - 0.25 | 0.25 - 0.25 |
| Close: | 0.27 - 0.27 | 0.27 - 0.27 |
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Mon, 15 Dec 2025
FibroBiologics (Nasdaq: FBLG) prices $1.7M direct sale and related $1.7M warrants - Stock Titan
Wed, 26 Nov 2025
FibroBiologics, Inc. Eliminates Convertible Debt and Advances Clinical Trials for Chronic Disease Treatments - Quiver Quantitative
Tue, 25 Nov 2025
FibroBiologics (Nasdaq: FBLG) closes $1.5M direct offering, $1.5M warrant potential - Stock Titan
Mon, 24 Nov 2025
FibroBiologics (Nasdaq: FBLG) prices $1.5M direct offering at $0.335 with private warrants - Stock Titan
Wed, 19 Nov 2025
FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Wed, 19 Nov 2025
FibroBiologics Announces $4 Million Registered Direct Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 4.321e+007 (%) |
| Held by Institutions | 11.7 (%) |
| Shares Short | 1,810 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.755e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -115.7 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.39e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|